DOCSLIB.ORG

Molecular Tools for G-Protein Coupled Receptors: Synthesis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Molecular Tools for G-Protein Coupled Receptors: Synthesis, Pharmacological Characterization and [3H]-Labeling of Subtype-selective Ligands for Histamine H4 and NPY Y2 Receptors Dissertation zur Erlangung des Doktorgrades der Naturwissenschaften (Dr. rer. nat.) an der Fakultät für Chemie und Pharmazie der Universität Regensburg vorgelegt von Paul Baumeister aus Zinzenzell 2014 Die vorliegende Arbeit entstand in der Zeit von April 2010 bis April 2014 unter der Anleitung von Herrn Prof. Dr. Armin Buschauer am Institut für Pharmazie der Naturwissenschaftlichen Fakultät IV – Chemie und Pharmazie – der Universität Regensburg. Das Promotionsgesuch wurde eingereicht im Juni 2014. Tag der mündlichen Prüfung: 18.07.2014 Prüfungsausschuss: Prof. Dr. J. Heilmann (Vorsitzender) Prof. Dr. A. Buschauer (Erstgutachter) Prof. Dr. S. Elz (Zweitgutachter) Prof. Dr. J. Wegener (Drittprüfer) „If you don’t turn your life into a story, you just become a part of someone else’s story.“ Terry Pratchett I Danksagung An dieser Stelle möchte mich ganz herzlich bei allen bedanken, die zum Gelingen dieser Arbeit beigetragen haben und mich während der Promotionszeit begleitet haben. Besonders möchte ich danken: Meinem Doktorvater Herrn Prof. Dr. Armin Buschauer für das Vertrauen und die Möglichkeit dieses interessante und herausfordernde Projekt zu verwirklichen, seine wissenschaftlichen Anregungen, für die mir gewährte forscherische Freiheit, seine konstruktive Kritik bei der Durchsicht der Arbeit, sein stets offenes Ohr, sowie die Mentorenschaft in der Emil-Fischer-Graduiertenschule; Herrn Prof. Dr. Günther Bernhardt für seine stete Hilfsbereitschaft und sein Interesse am Fortschritt der Arbeit, sein Fachwissen, die Durchsicht der Arbeit, die Co-Mentorenschaft in der Emil-Fischer- Graduiertenschule, sowie für hervorragenden Sommerfeste; Herrn Prof. Dr. Sigurd Elz für die Erstellung des Zweitgutachtens und die Teilnahme an der mündlichen Prüfung; Herrn Prof. Dr. Joachim Wegener für die Bereitschaft als Drittprüfer an der mündlichen Prüfung teilzunehmen und die Co-Mentorenschaft in der Emil-Fischer-Graduiertenschule; Herrn Prof. Dr. Jörg Heilmann für die Teilnahme als Vorsitzender in der mündlichen Prüfung; Herrn Dr. Max Keller für seine fachliche und soziale Kompetenz, die hervorragende Zusammenarbeit, aufmunternde Worte, seine Motivation, die Bereitstellung von Synthesebausteinen und die gemütlichen Abende bei selbstgemachtem Wein; Herrn Dr. Patrick Igel und Herrn Dr. Roland Geyer für die ausführliche Einführung in die Histamin- Welt, die fachlichen Tipps und die Bereitstellung von Synthesebausteinen; Herrn Dr. Nikola Pluym für die ausführliche Einführung in die NPY-Welt, die fachlichen Diskussionen, seine soziale Kompetenz, die Bereitstellung von Synthesebausteinen und die Einführung in die Welt der Radioligandsynthese; Herrn Dr. Thilo Spruss, Herrn Franz Wiesenmayer und Frau Petra Pistor für die Betreuung und Unterstützung bei der Durchführung der Tierversuche, sowie für das Anfertigen der Kryoschnitte von Gewebeproben und deren histologischen Färbung; Herrn Dr. Uwe Nordemann für die Durchführung der HEK293 Zellexperimente mit [3H]JNJ7777120 und die Einweisung in die Welt der Radioligandsynthese; Frau Nicole Kagermeier für die fachlichen Diskussionen und die Durchführung der HEK293 Zellexperimente mit [3H]UR-DE257; Frau Maria Beer‐Krön, Frau Dita Fritsch, Frau Susanne Bollwein, Frau Elvira Schreiber und Frau Brigitte Wenzl für die tatkräftige Unterstützung bei der Durchführung vieler Assays, HPLC-Läufe und der Zellkultivierung; Herrn Peter Richthammer für die zahlreichen netten Gespräche, seine stete Hilfsbereitschaft und Kompetenz bei allen technischen Herausforderungen und für die gute Zusammenarbeit bei der Durchführung der verschiedenen Praktika; Frau Uta Hasselmann, Frau Karin Reindl und Frau Silvia Heinrich für die stets freundliche Unterstützung bei allen organisatorischen Angelegenheiten; II Frau Edith Bartole, Frau Shiwen Xue, Herrn Josef Auburger, Herrn Michael Schupfner und Herrn Markus Friedrich für die Durchführung von Versuche im Rahmen Ihrer Praktika; Allen Laborkollegen, allen Mitgliedern der Histamin-Gruppe und der NPY-Gruppe für die angenehme, inspirierenden und gelegentlich auch amüsanten Atmosphäre und die sehr gute Zusammenarbeit; Frau Edith Bartole und Frau Sabrina Biselli für die gute Zusammenarbeit im Rahmen der Betreuung Ihrer Masterarbeiten; Allen Mitarbeitern der analytischen Abteilung der Universität Regensburg für die Aufnahme und Hilfestellung bei der Interpretation der NMR- und Massenspektren. Ein besonderer Dank geht hierbei an Herrn Fritz Kastner und Herrn Josef Kiermaier für die hilfreichen Diskussionen und die Ermittlung zahlreicher analytischer Daten; Allen Mitgliedern der Arminia Buschauer für die tolle Zeit am Lehrstuhl, die stets gute Kollegialität, Arbeitsatmosphäre und Zusammenarbeit; Frau Dr. Stefanie Bauer, Herrn Dr. Roland Geyer, Herrn Stefan Huber, Frau Nicole Kagermeier, Herrn Dr. Nikola Pluym, Frau Edith Bartole, Herrn Steffen Pockes und Frau Maria Beer-Kroen für die vielen netten Gespräche und schöne Zeit; Den Mitarbeitern der FAU Erlangen, Herrn Prof. Dr. Peter Gmeiner, Herrn Prof. Dr. Markus Heinrich, Frau Dr. Nuska Tschammer, Herrn Dr. Viachaslau Bernat, Herrn Dr. Harald Hübner und Michael Fürst für die gute Zusammenarbeit; Herrn Prof. Dr. Oliver Reiser und Dr. Julian Bodensteiner für die gute Zusammenarbeit; Der Deutschen Forschungsgemeinschaft für die finanzielle Förderung im Rahmen des Graduiertenkollegs GRK 760; Special thanks to my coworkers and friends Jianfei Wan and Xueke She for the great opportunity to visit their homeland China, all the hospitality, patience and unforgettable impressions. 谢谢! 干杯! Meinen Freunden und dem Trimmverein Regensburg, auf die man sich immer verlassen konnte, wenn es darauf ankam. ‚Reich sind nur die, die wahre Freunde haben‘ (Thomas Fuller); Den Herren Dr. Daniel Bücherl, Petr Jirásek und Michel Leonhardt für die allmorgendliche Frühstücksrunde, sowie die moralische und fachliche Unterstützung; Zuletzt all denjenigen, die das Leben lebenswert machen und mehr als nur Dank verdienen: meinen Eltern, meinen Geschwistern und meiner Freundin Marina. Ihnen ist die vorliegende Arbeit gewidmet. III Publications (published results prior to the submission of this thesis): (1) Baumeister, P., Erdmann, D., Biselli, S., Kagermeier, N., Bernhardt, G., Buschauer, A.: [3H]UR- DE257: A Selective and Highly Potent Tritium-Labeled Squaramide-type Histamine H2 Receptor Antagonist. ChemMedChem 2014, in preparation. (2) Geyer, R., Kaske, M., Baumeister, P., Buschauer, A.: Synthesis and Functional Characterization of Imbutamine Analogs as Histamine H3 and H4 Receptor Ligands. Arch. Pharm. Chem. Life Sci. 2014, 347, 77–88. (3) Pluym, N., Baumeister, P., Keller, M., Bernhardt, G., Buschauer, A.: [3H]UR-PLN196: A Selective Nonpeptide Radioligand and Insurmountable Antagonist for the Neuropeptide Y Y2 Receptor. ChemMedChem Comm. 2013, 8, 587-593. (4) Bodensteiner, J., Baumeister, P., Geyer, R., Buschauer, A., Reiser, O.: Synthesis and Pharmacological Characterization of New Tetrahydrofuran Based Compounds as Conformationally Constrained Histamine Receptor Ligands. Org. Biomol. Chem. 2013, 11, 4040-4055. (5) Bernat, V., Heinrich, M., Baumeister, P., Buschauer, A., Tschammer, N.: Synthesis and Application of the First Radioligand Targeting the Allosteric Binding Pocket of Chemokine Receptor CXCR3. ChemMedChem 2012, 7 (8), 1481-1489. Short Lecture: Baumeister, P.: The First Selective Tritium-labeled Nonpeptide Radioligands for the NPY Y2 Receptor. Christmas Colloquium 2012 of the Department of Organic Chemistry, University of Regensburg, 19.12.2012. Poster Presentations: 03/2013 Annual Meeting of the GDCh, Fachgruppe Medizinische Chemie, Frontiers in Medicinal Chemistry, München. Baumeister, P., Pluym, N., Keller, M., Bernhardt, G., Buschauer, A.: Subtype-selective Nonpeptide NPY Y2 Receptor Radioligands. 09/2012 XXIInd International Symposium on Medicinal Chemistry (ISMC), Berlin. Baumeister, P., Erdmann, D., Bernhardt, G., Buschauer, A.: [3H]UR-DE257: A New Tritium-labeled Histamine H2 Receptor Antagonist. Bernat, V., Heinrich, M., Baumeister, P., Buschauer, A., Tschammer, N.: Synthesis and Application of the First Small-Molecule Radioligand Targeting the Human Chemokine Receptor CXCR3. Best Poster Award IV 09/2012 6th Summer School in Medicinal Chemistry, Regensburg. Geyer, R., Nordemann, U., Baumeister, P., Bernhardt, G., Buschauer, A.: trans‐(+)‐(1S,3S)‐UR‐RG98: Synthesis, Absolute Configuration and Pharmacological Characterization of a Highly Potent and Selective Histamine H4 Receptor Agonist. 03/2011 Annual Meeting of the GDCh, Fachgruppe Medizinische Chemie, Frontiers in Medicinal Chemistry, Saarbrücken. Baumeister, P., Buschauer, A.: 2-Arylbenzimidazoles as Potent Human Histamine H4 Receptor Agonists. Professional Training: 04/2013 Fortbildung für Projektleiter und Beauftragter für Biologische Sicherheit (§15 und 17 Gentechniksicherheitsverordnung). Regensburg, Germany. 06/2010 Umgang mit offenen radioaktiven Stoffen. Regensburg, Germany. 03/2010 – 03/2012 Member of the Research Training Group (Graduiertenkolleg 760) “Medicinal Chemistry: Molecular Recognition – Ligand Receptor Interactions” of the German Research Foundation. Regensburg, Germany. 06/2012 – 04/2014 Member of the Emil Fischer Graduate School of Pharmaceutical Sciences and Molecular Medicine. Regensburg, Erlangen, Germany. V Contents 1 Introduction ..........................................................................................................................
Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active

    TABLE 1 Studies of Antagonist Activity in Constitutively Active

    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
  • From Inverse Agonism to 'Paradoxical Pharmacology' Richard A

    From Inverse Agonism to 'Paradoxical Pharmacology' Richard A

    International Congress Series 1249 (2003) 27-37 From inverse agonism to 'Paradoxical Pharmacology' Richard A. Bond*, Kenda L.J. Evans, Zsirzsanna Callaerts-Vegh Department of Pharmacological and Pharmaceutical Sciences, University of Houston, 521 Science and Research Bldg 2, 4800 Caltioun, Houston, TX 77204-5037, USA Received 16 April 2003; accepted 16 April 2003 Abstract The constitutive or spontaneous activity of G protein-coupled receptors (GPCRs) and compounds acting as inverse agonists is a recent but well-established phenomenon. Dozens of receptor subtypes for numerous neurotransmitters and hormones have been shown to posses this property. However, do to the apparently low percentage of receptors in the spontaneously active state, the physiologic relevance of these findings remains questionable. The possibility that the reciprocal nature of the effects of agonists and inverse agonists may extend to cellular signaling is discussed, and that this may account for the beneficial effects of certain p-adrenoceptor inverse agonists in the treatment of heart failure. © 2003 Elsevier Science B.V. All rights reserved. Keywords. Inverse agonism; GPCR; Paradoxical pharmacology 1. Brief history of inverse agonism at G protein-coupled receptors For approximately three-quarters of a century, ligands that interacted with G protein- coupled receptors (GPCRs) were classified either as agonists or antagonists. Receptors were thought to exist in a single quiescent state that could only induce cellular signaling upon agonist binding to the receptor to produce an activated state of the receptor. In this model, antagonists had no cellular signaling ability on their own, but did bind to the receptor and prevented agonists from being able to bind and activate the receptor.
  • Histamine Receptors

    Histamine Receptors

    Tocris Scientific Review Series Tocri-lu-2945 Histamine Receptors Iwan de Esch and Rob Leurs Introduction Leiden/Amsterdam Center for Drug Research (LACDR), Division Histamine is one of the aminergic neurotransmitters and plays of Medicinal Chemistry, Faculty of Sciences, Vrije Universiteit an important role in the regulation of several (patho)physiological Amsterdam, De Boelelaan 1083, 1081 HV, Amsterdam, The processes. In the mammalian brain histamine is synthesised in Netherlands restricted populations of neurons that are located in the tuberomammillary nucleus of the posterior hypothalamus.1 Dr. Iwan de Esch is an assistant professor and Prof. Rob Leurs is These neurons project diffusely to most cerebral areas and have full professor and head of the Division of Medicinal Chemistry of been implicated in several brain functions (e.g. sleep/ the Leiden/Amsterdam Center of Drug Research (LACDR), VU wakefulness, hormonal secretion, cardiovascular control, University Amsterdam, The Netherlands. Since the seventies, thermoregulation, food intake, and memory formation).2 In histamine receptor research has been one of the traditional peripheral tissues, histamine is stored in mast cells, eosinophils, themes of the division. Molecular understanding of ligand- basophils, enterochromaffin cells and probably also in some receptor interaction is obtained by combining pharmacology specific neurons. Mast cell histamine plays an important role in (signal transduction, proliferation), molecular biology, receptor the pathogenesis of various allergic conditions. After mast cell modelling and the synthesis and identification of new ligands. degranulation, release of histamine leads to various well-known symptoms of allergic conditions in the skin and the airway system. In 1937, Bovet and Staub discovered compounds that antagonise the effect of histamine on these allergic reactions.3 Ever since, there has been intense research devoted towards finding novel ligands with (anti-) histaminergic activity.
  • BRS Pharmacology

    BRS Pharmacology

    Pharmacology Gary C. Rosenfeld, Ph.D. Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences Assistant Dean for Education Programs University of Texas Medical School at Houston Houston, Texas David S. Loose, Ph.D. Associate Professor Department of Integrated Biology and Pharmacology and Graduate School of Biomedical Sciences University of Texas Medical School at Houston Houston, Texas With special contributions by Medina Kushen, M.D. William Beaumont Hospital Royal Oak, Michigan Todd A. Swanson, M.D., Ph.D. William Beaumont Hospital Royal Oak, Michigan Acquisitions Editor: Charles W. Mitchell Product Manager: Stacey L. Sebring Marketing Manager: Jennifer Kuklinski Production Editor: Paula Williams Copyright C 2010 Lippincott Williams & Wilkins 351 West Camden Street Baltimore, Maryland 21201-2436 USA 530 Walnut Street Philadelphia, PA 19106 All rights reserved. This book is protected by copyright. No part of this book may be reproduced in any form or by any means, including photocopying, or utilized by any information storage and retrieval system without written permission from the copyright owner. The publisher is not responsible (as a matter of product liability, negligence or otherwise) for any injury resulting from any material contained herein. This publication contains information relating to general principles of medical care which should not be construed as specific instructions for individual patients. Manufacturers’ product information and package inserts should be reviewed for current information, including contraindications, dosages and precautions. Printed in the United States of America Library of Congress Cataloging-in-Publication Data Rosenfeld, Gary C. Pharmacology / Gary C. Rosenfeld, David S. Loose ; with special contributions by Medina Kushen, Todd A.
  • In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists

    In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs As Inverse H1 Receptor Agonists

    0022-3565/07/3221-172–179$20.00 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS Vol. 322, No. 1 Copyright © 2007 by The American Society for Pharmacology and Experimental Therapeutics 118869/3215703 JPET 322:172–179, 2007 Printed in U.S.A. In Vitro Pharmacology of Clinically Used Central Nervous System-Active Drugs as Inverse H1 Receptor Agonists R. A. Bakker,1 M. W. Nicholas,2 T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Department of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands (R.A.B., H.T., R.L.); ACADIA Pharmaceuticals Inc., San Diego, California (R.A.B., M.W.N., T.T.S., E.S.B., U.H., M.R.B., D.M.W.); and Departments of Pharmacology (M.R.B.), Neurosciences (D.M.W.), and Psychiatry (D.M.W.), University of California, San Diego, California Received January 2, 2007; accepted March 30, 2007 Downloaded from ABSTRACT The human histamine H1 receptor (H1R) is a prototypical G on this screen, we have reported on the identification of 8R- protein-coupled receptor and an important, well characterized lisuride as a potent stereospecific partial H1R agonist (Mol target for the development of antagonists to treat allergic con- Pharmacol 65:538–549, 2004). In contrast, herein we report on jpet.aspetjournals.org ditions. Many neuropsychiatric drugs are also known to po- a large number of varied clinical and chemical classes of drugs tently antagonize this receptor, underlying aspects of their side that are active in the central nervous system that display potent effect profiles.
  • Product Information

    Product Information

    Print Date: Oct 31st 2017 Product Information www.tocris.com Product Name: Histamine H3 Receptor Tocriset™ Catalog No.: 1876 Batch No.: 1 1. Tocriset™ Description A Tocriset™ consists of 3 to 5 key compounds that are active within a defined pharmacological area or a signaling pathway. Most compounds are supplied in a solid format in a specified molar amount so that solvent can be added directly to the vial. For example, addition of 500 μL of solvent to a vial containing 5 μmol of compound yields a 10 mM stock solution. Some compounds that are unsuitable for lyophilization are provided pre-dissolved in DMSO. The Histamine H3 Receptor Tocriset™ contains the listed products as lyophilised solids which can be used to study the pharmacology of the histamine H3 receptor. Cat.No. Product / Activity Batch Amount Format 0569 (R)-(-)-α-Methylhistamine dihydrobromide 7 5 μmol Freeze-dried solid Potent, selective H3 agonist 0644 Thioperamide 7 5 μmol Freeze-dried solid H3 antagonist, active in vivo 0729 Imetit dihydrobromide 2 5 μmol Freeze-dried solid Standard selective H3 agonist 0752 Clobenpropit dihydrobromide 2 5 μmol Freeze-dried solid Highly potent, selective H3 antagonist 0779 Iodophenpropit dihydrobromide 2 5 μmol Freeze-dried solid Potent, selective H3 antagonist 2. Storage & Solubility SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt. SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month, unless indicated below.
  • Complete Dissertation

    Complete Dissertation

    VU Research Portal Histamine H3-receptors in the central nervous systems of rats and mice Jansen, F.P. 1997 document version Publisher's PDF, also known as Version of record Link to publication in VU Research Portal citation for published version (APA) Jansen, F. P. (1997). Histamine H3-receptors in the central nervous systems of rats and mice. General rights Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain • You may freely distribute the URL identifying the publication in the public portal ? Take down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. E-mail address: [email protected] Download date: 24. Sep. 2021 Histamine H3-receptors· in the central nervous system of rats and mice Characteristics, distribution and function studied with [l25I]iodophenpropit Ph.D.-thesis Most of the research described in this thesis was performed at the Division of Molecular Pharmacology of the Leiden/Amsterdarn Center for Drug Research (LACDR), Department ofPharmacochernistry, Vrije Universiteit, De Boelelaan 1083, 1081HV, Amsterdam, The Netherlands. Some of the investigations were carried out in close collaboration with other institutes.
  • G Protein-Coupled Receptors

    G Protein-Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
  • G Protein‐Coupled Receptors

    G Protein‐Coupled Receptors

    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: G protein-coupled receptors. British Journal of Pharmacology (2019) 176, S21–S141 THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors Stephen PH Alexander1 , Arthur Christopoulos2 , Anthony P Davenport3 , Eamonn Kelly4, Alistair Mathie5 , John A Peters6 , Emma L Veale5 ,JaneFArmstrong7 , Elena Faccenda7 ,SimonDHarding7 ,AdamJPawson7 , Joanna L Sharman7 , Christopher Southan7 , Jamie A Davies7 and CGTP Collaborators 1School of Life Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK 2Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, Victoria 3052, Australia 3Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK 4School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, BS8 1TD, UK 5Medway School of Pharmacy, The Universities of Greenwich and Kent at Medway, Anson Building, Central Avenue, Chatham Maritime, Chatham, Kent, ME4 4TB, UK 6Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK 7Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared to information and links presented on the website.
  • International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

    International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors

    1521-0081/67/3/601–655$25.00 http://dx.doi.org/10.1124/pr.114.010249 PHARMACOLOGICAL REVIEWS Pharmacol Rev 67:601–655, July 2015 Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics ASSOCIATE EDITOR: ELIOT H. OHLSTEIN International Union of Basic and Clinical Pharmacology. XCVIII. Histamine Receptors Pertti Panula, Paul L. Chazot, Marlon Cowart, Ralf Gutzmer, Rob Leurs, Wai L. S. Liu, Holger Stark, Robin L. Thurmond, and Helmut L. Haas Department of Anatomy, and Neuroscience Center, University of Helsinki, Finland (P.P.); School of Biological and Biomedical Sciences, University of Durham, United Kingdom (P.L.C.); AbbVie, Inc. North Chicago, Illinois (M.C.); Department of Dermatology and Allergy, Hannover Medical School, Hannover, Germany (R.G.); Department of Medicinal Chemistry, Amsterdam Institute of Molecules, Medicines and Systems, VU University Amsterdam, The Netherlands (R.L.); Ziarco Pharma Limited, Canterbury, United Kingdom (W.L.S.L.); Institute of Pharmaceutical and Medical Chemistry (H.S.) and Institute of Neurophysiology, Medical Faculty (H.L.H.), Heinrich-Heine-University Duesseldorf, Germany; and Janssen Research & Development, LLC, San Diego, California (R.L.T.) Abstract ....................................................................................602 Downloaded from I. Introduction and Historical Perspective .....................................................602 II. Histamine H1 Receptor . ..................................................................604 A. Receptor Structure
  • Neuroscience Products

    Neuroscience Products

    Neuroscience Products CATALOG CATALOG NUMBER U.S. $ NUMBER U.S. $ -A- 3-(N-ACETYLAMINO)-5-(N-DECYL-N- 1 mg 27.50 159549 METHYLAMINO)BENZYL ALCOHOL 5 mg 89.40 o A23187 0-5 C [103955-90-4] (ADMB) See: Antibiotic A23187 A Protein Kinase C activator. Ref.: Proc. Nat. Acad. Sci. USA, 83, 4214 AA-861 20 mg 72.70 (1986). 159061 Purity: 95% 100 mg 326.40 C20H34N2O2 MW 334.5 0oC Orally active, specific and potent inhibitor of 5-lipoxygenase. N-ACETYL-ASP-GLU 25 mg 45.00 153036 [3106-85-2] 100 mg 156.00 Ref.: 1. Yoshimoto, T., et.al., Biochim. o Biophys. Acta, 713, 470 (1982). 2. Ashida, -20-0 C An endogenous neuropeptide with high 250 mg 303.65 Y., et.al., Prostaglandins, 26, 955 (1983). 3. affinity for a brain "Glutamate" receptor. Ancill, R.J., et.al., J. Int. Med. Res., 18, 75 Ref: Zaczek, R., et al., Proc. Natl. Acad. (1990). Sci. (USA), 80, 1116 (1983). C21H26O3 MW 326.4 C11H16N2O8 MW 304.3 ABL PROTEIN TYROSINE KINASE 250 U 47.25 N-ACETYL-2-BENZYLTRYPTAMINE 195876 (v-abl) 1 KU 162.75 See: Luzindole -70oC Recombinant Expressed in E. coli ACETYL-DL-CARNITINE 250 mg 60.00 A truncated form of the v-abl protein 154690 [2504-11-2] 1 g 214.00 tyrosine kinase which contains the 0oC Hydrochloride minimum region needed for kinase activity Crystalline and fibroblast transformation. Suppresses C9H17NO4 • HCl MW 239.7 apoptosis and induces resistance to anti-cancer compounds. O-ACETYL-L-CARNITINE CHLORIDE 500 mg 11.45 Activity: 100 KU/ml 159062 [5080-50-2] 1 g 20.65 Unit Definition: one unit is the amount of 0-5oC (R-(-)-2-Acetyloxy-3-carboxy-N,N,N-trimethyl 5 g 97.45 enzyme which catalyzes the transfer of 1 -1-propanaminium chloride) pmol of phosphate to EAIYAAPFAKKK per Purity: >88% minute at 30°C, pH 7.5.
  • WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T

    WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/085719 Al 5 June 2014 (05.06.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61M 15/00 (2006.01) A24F 47/00 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US20 13/072426 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 27 November 2013 (27.1 1.2013) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: ZW. 61/730,738 28 November 2012 (28. 11.2012) US 61/794,601 15 March 2013 (15.03.2013) US (84) Designated States (unless otherwise indicated, for every 61/83 1,992 6 June 2013 (06.06.2013) us kind of regional protection available): ARIPO (BW, GH, 61/887,045 4 October 201 3 (04.